Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...

Bio-Rad Laboratories, Inc. (BIO) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close.

Growing demand for sensitive and accurate nucleic acid detection, wider use in clinical diagnostics and personalized medicine ...

We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Bio-Rad Laboratories, Inc. is among the ...

Bio-Rad Laboratories stock draws attention after trend movement. Explore drivers, sector position, and healthcare technology ...

Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the ...

Rad, explores how droplet digital PCR (ddPCR) overcomes limitations of traditional PCR, reshaping how scientists approach ...

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”. A copy of the letter can be downloaded here. The Fund seeks to ...

Longleaf Partners Global Fund said that it ended the first quarter of 2026 with a P/V in the mid-50s%. The fund, in its quarterly commentary, said that FedEx and Glanbia were top ...

During the quarter Longleaf Partners Global Fund had no new purchases and exited four holdings: Bio-Rad, Louis Hachette, ...

The metastatic breast cancer (mBC) landscape is evolving rapidly due to the increasing prevalence of ESR1 mutations, a key driver for hormone receptor-positive (HR+) patients. ESR1 mutations, ...